News
PTN
14.41
-3.45%
-0.52
Palatin price target lowered to $47.50 from $50 at Alliance Global
TipRanks · 2d ago
Palatin Technologies Earnings Call: Partnerships, Progress, Risks
TipRanks · 2d ago
Transcript: Palatin Techs Q3 2026 Earnings Conference Call
Benzinga · 3d ago
Palatin Is Betting on the Next Generation of Obesity Drugs (NYSE: PTN)
TipRanks · 3d ago
Palatin Techs Q3 EPS $(0.37) Beats $(1.26) Estimate, Sales $3.921M Beat $1.283M Estimate
Benzinga · 3d ago
Palatin Technologies GAAP EPS of -$0.37, revenue of $3.9M
Seeking Alpha · 3d ago
*Palatin Technologies: Runway To Fund Operations Through June 2027 >PTN
Dow Jones · 3d ago
*Palatin Technologies 3Q Rev $3.92M >PTN
Dow Jones · 3d ago
*Palatin Technologies 3Q Loss/Shr 37c >PTN
Dow Jones · 3d ago
Press Release: Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 3d ago
Press Release: Palatin Reports Fiscal Third -2-
Dow Jones · 3d ago
Weekly Report: what happened at PTN last week (0504-0508)?
Weekly Report · 5d ago
Weekly Report: what happened at PTN last week (0427-0501)?
Weekly Report · 05/04 09:44
Weekly Report: what happened at PTN last week (0420-0424)?
Weekly Report · 04/27 09:45
Weekly Report: what happened at PTN last week (0413-0417)?
Weekly Report · 04/20 09:44
Weekly Report: what happened at PTN last week (0406-0410)?
Weekly Report · 04/13 09:45
Weekly Report: what happened at PTN last week (0330-0403)?
Weekly Report · 04/06 09:45
Weekly Report: what happened at PTN last week (0323-0327)?
Weekly Report · 03/30 09:45
Weekly Report: what happened at PTN last week (0316-0320)?
Weekly Report · 03/23 09:43
Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)
TipRanks · 03/20 13:30
More
Webull provides a variety of real-time PTN stock news. You can receive the latest news about Palatin Tech through multiple platforms. This information may help you make smarter investment decisions.
About PTN
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. The MCR system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. Its product development activities focus primarily on the use of MC4R agonists for treatment of obesity. It develops MC4R peptides and small molecule agonists with potential utility in obesity and metabolic-related disorders, rare MC4R pathway diseases, such as hypothalamic obesity, and orphan indications. It also develops MC1R agonist products to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease.